Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor

OncoAlert and ecancer weekly roundup for November 2 - 7, 2020

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer

PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer

Sotorasib for advanced non-small cell lung cancer

VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma

Prospective validation of single mouse testing by the paediatric preclinical testing consortium

The ENA virtual meeting 2020

Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients

Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation

Development of novel inhibitors of KRASG12C

Impact of angiotensin II pathway inhibition on tumour response to anti PD(L)1 based therapy